Fact based stock research
Carl Zeiss Meditec (XTRA:AFX)


Carl Zeiss Meditec stock research in summary

tec.zeiss.com


Carl Zeiss Meditec shares have a HOLD rating. They are safely financed and show above average growth, but are bad value. We recommend holding Carl Zeiss Meditec shares.


Latest Obermatt Ranks


Country Germany
Industry Health Care Equipment
Index TecDAX, CDAX
Size class Medium

March 22, 2018. Top 10 stocks updated on Top 10 schedule or at least quarterly. ()


Achievements

Top 10 Stock






 

Research History: Carl Zeiss Meditec

STOCK RESEARCH SUMMARY 2015 2016 2017 2018
STOCK VALUE RANKS
58
38
32
33
STOCK GROWTH RANKS
78
64
73
62
STOCK SAFETY RANKS
1
93
61
71
COMBINED STOCK RANKS
11
86
64
62

Last update of Combined Rank: 22-Mar-2018. Stock research history is based on the Obermatt Method. The higher the rank, the better is Carl Zeiss Meditec in the corresponding investment strategy.


Value Metrics in Detail

Last update of Value Rank: 22-Mar-2018. Stock analysis on value ratios: The higher the rank, the lower the value ratio of Carl Zeiss Meditec; except for dividend yield where the rank is higher, the higher the yield.


Growth Metrics in Detail

GROWTH METRICS 2015 2016 2017 2018
REVENUE GROWTH
55
16
68
50
PROFIT GROWTH
77
67
61
59
STOCK RETURNS
71
78
70
87
CONSOLIDATED RANK: GROWTH
78
64
73
62

Financial reporting date of Growth Rank: 31-Dec-2017. Stock analysis on growth metrics: The higher the rank, the higher the growth and returns of Carl Zeiss Meditec.


Safety Metrics in Detail

SAFETY METRICS 2015 2016 2017 2018
LEVERAGE
44
87
51
49
REFINANCING
66
62
LIQUIDITY
1
93
61
69
CONSOLIDATED RANK: SAFETY
1
93
61
71

Financial reporting date of Safety Rank: 31-Dec-2017. Stock analysis on safety metrics: The higher the rank, the lower the leverage of Carl Zeiss Meditec and the more cash is available to service its debt.


Stock analysis by the purely financial fact-based Obermatt Method for the investment strategies Value, Growth and Safety for Carl Zeiss Meditec from March 22, 2018.